ISSN: 1525-7304

Journal Home

Journal Guideline

Clinical Lung Cancer Q1 Unclaimed

Elsevier Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Clinical Lung Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 74. It has an SJR impact factor of 1,263 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,263.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1) Pulmonary and Respiratory Medicine (Q1) Cancer Research (Q2)

Price

- €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,263

SJR Impact factor

74

H Index

137

Total Docs (Last Year)

530

Total Docs (3 years)

4023

Total Refs

1756

Total Cites (3 years)

487

Citable Docs (3 years)

3.23

Cites/Doc (2 years)

29.36

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Best articles by citations

1999 Highlights From: 10th European Cancer Conference, Vienna, Austria; 17th Chemotherapy Foundation Symposium, New York City, New York

Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18 FDG-PET/CT

Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review

Highlights From: 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida May 18-21, 2002

Selected Clinical Trials in Lung Cancer

Docetaxel Plus Cisplatin Combinations in Advanced Non - Small-Cell Lung Cancer

Highlights From: 97th Annual Meeting of the American Association for Cancer Research; Washington, DC, April 2006

Selected Clinical Trials in Lung Cancer

SHOW MORE ARTICLES

Selected Clinical Trials in Non-Small-Cell Lung Cancer

Commentary on "Effectiveness of Radiation Therapy on Non-Small-Cell Lung Cancer"

Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

Commentary on "Endoscopic Laser Ablation as Palliative Treatment of Endobronchial, Nonresectable, or Recurrent Lung Cancer: Assessment of its Impact on Quality of Life"

Commentary on "Growth-Stimulating Pathways in Lung Cancer: Implications for Targets of Therapy"

Commentary on "Image-Guided Fine Needle Aspirate Strategies for Staging of Lung Cancer"

Commentary on "Induction and Concurrent Paclitaxel/Carboplatin Every 3 Weeks with Thoracic Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: An Interim Report"

Small Molecule Inhibitors of the Epidermal Growth Factor Receptor in Patients with Non-Small-Cell Lung Cancer An Update of Clinical Data from the 2001 American Society of Clinical Oncology Meeting

Commentary on "Intraluminal Brachytherapy for Malignant Endobronchial Tumors: An Update on Low-Dose Rate Versus High-Dose Rate Radiation Therapy"

Clinical Development of Vandetanib: A Review of Ongoing Phase III Clinical Trials in Advanced NSCLC

Commentary on "Lung Cancer Screening in High-Risk Populations"